SCHEMBL29564521

SCHEMBL29564521

[2H]C([2H])([2H])C(CO)(NC(C)C(=O)c1cccc(Cl)c1)C([2H])([2H])[2H]

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.83
SLC6A2 P23975 7/20 0.65
SLC6A3 Q01959 6/20 0.65
CHRNA1 P02708 4/20 0.65
CHRNG P07510 4/20 0.65
CHRNB1 P11230 4/20 0.65
CHRNB2 P17787 4/20 0.65
CHRNB4 P30926 4/20 0.65
CHRNA3 P32297 4/20 0.65
CHRNA4 P43681 4/20 0.65
CHRND Q07001 4/20 0.65
SLC6A4 P31645 3/20 0.65
ITGA5 P08648 1/20 0.65
CYP2C19 P33261 1/20 0.65
HRH1 P35367 1/20 0.65
CHRNA7 P36544 1/20 0.65
OPRK1 P41145 1/20 0.65
KCNH2 Q12809 1/20 0.65
ALDH1A1 P00352 2/20 0.64
BLM P54132 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955633 0.91 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL29486913 0.91 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL1226857 0.91 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL2955630 0.91 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL13416071 0.84 SLC6A2 (0.81) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL15478523 0.83 CYP2B6 (0.80) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL13001623 0.80 CYP2B6 (0.74) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL38777 0.79 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL12499296 0.79 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL29424575 0.79 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119555831-A Liquid chromatography mass spectrometry detection method for simultaneously measuring seven key probe substrate metabolites in CYP (CYP inhibition) inhibition test 上海药明康德新药开发有限公司 2025-03-04 CN claimed
CN-114778747-B Method for simultaneously detecting 16 drugs and metabolites thereof in blood by UPLC-MS/MS method 北京和合医学诊断技术股份有限公司 2022-09-02 CN claimed
CN-114778747-A Method for simultaneously detecting 16 drugs and metabolites thereof in blood by UPLC-MS/MS method 北京和合医学诊断技术股份有限公司 2022-07-22 CN claimed
EP-3977138-A1 DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY Quest Diagnostics Investments LLC (US) 2022-04-06 EP claimed
US-12584111-B2 Compositions and methods for long term culture of hepatocytes PEKING UNIVERSITY (CN) 2026-03-24 US disclosed
US-20250349528-A1 DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY QUEST DIAGNOSTICS INVEST LLC (US) 2025-11-13 US disclosed
US-12394612-B2 Determination of antidepressants by mass spectrometry QUEST DIAGNOSTICS INVESTMENTS LLC (US) 2025-08-19 US disclosed
CN-114127554-B Determination of antidepressants by mass spectrometry 奎斯特诊断投资有限公司 2025-06-13 CN disclosed
CN-119555831-A Liquid chromatography mass spectrometry detection method for simultaneously measuring seven key probe substrate metabolites in CYP (CYP inhibition) inhibition test 上海药明康德新药开发有限公司 2025-03-04 CN disclosed
CN-118878511-A Adamantane derivative, PROTAC degradation agent targeting ER, preparation method and application thereof 晨伫(杭州)生物科技有限责任公司 2024-11-01 CN disclosed
CN-118812505-A PI5P4K gamma inhibitor compound, pharmaceutical composition, and preparation method and application thereof 贵州医科大学 2024-10-22 CN disclosed
US-20240120188-A1 DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY QUEST DIAGNOSTICS INVEST LLC (US) 2024-04-11 US disclosed
US-11887828-B2 Determination of antidepressants by mass spectrometry QUEST DIAGNOSTICS INVESTMENTS LLC (US) 2024-01-30 US disclosed
US-11613735-B2 Methods for reprograming non-hepatocyte cells into hepatocyte cells BEIHAO STEM CELL AND REGENERATIVE MEDICINE TRANSLATIONAL RESEARCH INSTITUTE (CN) 2023-03-28 US disclosed
CN-114778747-B Method for simultaneously detecting 16 drugs and metabolites thereof in blood by UPLC-MS/MS method 北京和合医学诊断技术股份有限公司 2022-09-02 CN disclosed
CN-114778747-A Method for simultaneously detecting 16 drugs and metabolites thereof in blood by UPLC-MS/MS method 北京和合医学诊断技术股份有限公司 2022-07-22 CN disclosed
US-20220135941-A1 COMPOSITIONS AND METHODS FOR LONG TERM CULTURE OF HEPATOCYTES PEKING UNIVERSITY (CN) 2022-05-05 US disclosed
EP-3977138-A1 DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY Quest Diagnostics Investments LLC (US) 2022-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584111-B2 Compositions and methods for long term culture of hepatocytes WNT3A, CTNNB1, WNT1 CYP2B6 1213/4885SLC6A2 2272/4885SLC6A3 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.